Gürsoy, Vildan2024-09-112024-09-112023-04-270041-1345https://doi.org/10.1016/j.transproceed.2023.02.020https://hdl.handle.net/11452/44532Aplastic anemia is potentially fatal, particularly if the disease does not respond to immunotherapy and progresses to severe pancytopenia. Allogeneic hematopoietic stem cell transplant from an HLA-matched sibling donor, the first-line treatment in patients younger than 40 years, is used as a curative treatment option in severe aplastic anemia. The availability of an identical twin donor is infrequent, and there is limited experience in this context. Additionally, the choices for a conditioning regimen for a syngeneic transplant to prevent engraftment failure and the necessity of graft-vs-host disease prophylaxis are controversial. Although long-term survival gradually increases after an allogeneic hematopoietic stem cell transplant, hypogonadism and infertility are the main problems that significantly affect patients' quality of life. We present a patient diagnosed with severe aplastic anemia who has had a healthy pregnancy immediately after a syngeneic transplant.eninfo:eu-repo/semantics/closedAccessStem-cell transplantationBloodScience & technologyLife sciences & biomedicineImmunologySurgeryTransplantationArticle00099045850000171571755310.1016/j.transproceed.2023.02.020